eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

ELIQUIS (apixaban): Simple dosing for stroke prevention in NVAF, with or without food

desk-img mob-img
  • In the ARISTOTLE clinical trial, the majority of patients were on 5 mg BD (95.3%, n = 8,692/9,120)2*
  • Liver function testing should be performed prior to initiating ELIQUIS1

ELIQUIS can be taken with or without food1

large x icon

Missed dose: if a dose is missed, the patient should take ELIQUIS immediately and then continue with twice-daily intake as before1

Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

* In the ARISTOTLE trial, a total of 18,201 patients with NVAF and one risk factor for stroke and mean CHADS2 score of 2.1 were randomised to ELIQUIS 5mg BD (or 2.5 mg BD in selected patients [4.7%]) or warfarin adjusted to target INR range range 2.0–3.0. Stroke or systemic embolism was the primary efficacy endpoint of the ARISTOTLE trial (hameorrhagic stroke and ischaemic or undetermined stroke were components of stroke) and major bleeding defined per International Society on Thrombosis and Heamostasis (ISTH) criteria were the primary endpoint. Efficacy analyses based on the intention-to-treat population. Safety analyses based on patients who had at least one dose of study drug.2

BD = Twice Daily   CHADS2 = Congestive heart failure, Hypertension, Age ≥75, Diabetes, Stroke (doubled)   CrCl = Creatine Clearance   INR = International Normalised Ratio   NVAF = Non-Valvular Atrial Fibrillation


  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. Granger CB et al. N Engl J Med 2011; 365: 981–992.